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SUMMARY
Nucleic Acid Testing (NAT) as a tool for primary screening of blood donors became a reality in the end of the 1990 decade. We
report here the development of an “in-house” RT-PCR method that allows the simultaneous (multiplex) detection of HCV and
HIV-RNA in addition to an artificial RNA employed as an external control. This method detects all HIV group M subtypes, plus
group N and O, with a detection threshold of 500 IU/mL. After validation, the method replaced p24 Ag testing, in use for blood
donation screening since 1996 at our services. From July 2001 to February 2006, 102,469 donations were tested and 41 (0.04%)
were found HIV-RNA reactive. One NAT-only reactive donation (antibody non-reactive) was observed, with subsequent
seroconversion of the implied donor, giving a yield of 1:102,469. This rate is in contrast to the international experience that reports
a detection of approximately 1:600,000 - 1:3,100,000 of isolated HIV-RNA donations.
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INTRODUCTION
The main driving force for NAT introduction in the blood bank, as
a tool for screening, was the recognized deficiency of HCV antibody
tests, in part due to the long window period observed for this agent, of
approximately 90 days. After HCV NAT was established, the next target
became HIV5. Even though several pharmacoeconomic studies pointed
to the low cost-benefit relationship for NAT HIV6, it was introduced
worldwide. This was justified by the premise that adding new targets
to an existing NAT assay would aggregate value to the test, but also
matching the zero tolerance claimed by the public opinion for HIV
transfusional transmission. An antigenic test (p24 Ag) had already been
implemented in the hope to shorten the window period, but results
were fairly disappointing, in comparison to the predicted yield of this
test before implantation17. In general, the observed yield of HIV NAT
was very low, ranging from 0 per million in several European countries
to 3.7 per million in Hong Kong, being the USA the country with the
largest number of donations tested (37,000,000) and a yield of 0.32/
1,000,000 obtained4. Germany was the pioneer country in the adoption
of NAT for blood screening, and up today, about 80% of the blood
supply in this country is tested by “in-house” procedures. There are
different molecular methods in place but all them have to comply with
the regulations of the Paul-Ehrlich Institute. After testing 21,700,000
donations the yield of HIV-NAT is similar to the USA, six window-
period donations were detected, giving a rate of 0.28 per million4.
Scotland and Ireland also have employed an “in-house” method for
their screening, beginning with HCV-RNA testing in July of 1999 and
HIV-RNA afterwards, in January of 2003. After testing 771,059
donations, one single HIV NAT-only donation has been detected7. All
these countries adopting “in-house” methods have used RT-PCR with
gel electrophoresis detection in an early phase, subsequently migrating
to real-time PCR, when this became available.
As we had introduced NAT HCV10,20 in 1998, our development was
framed by the idea of within a similar methodological configuration,
add HIV-RNA testing, at a minimal increase in cost and without
affecting the sensitivity and overall performance of the test.
Towards that, we decided to include HIV-RNA in the existing
system, as a third target in a multiplex RT-PCR reaction (HCV, external
control and HIV). Several primer pairs were challenged with great
variability in sensitivity and specificity. All changeable parameters in
the PCR reaction were tested: magnesium chloride concentration,
amount of polymerase and cycling incubation time/temperature. After
two years, the method was considered ready to go, and submitted to an
extensive validation phase. We present here a description of the method
plus validation data and results obtained in routine application.
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MATERIAL AND METHODS
a) Donors and donations: Voluntary blood donors gave written
informed consent for participation in this ongoing study. For this
purpose a Serum Separation Tube (SST II, Becton-Dickinson, São
Paulo, Brazil) was drawn right after collection of the blood bag. Tubes
were centrifuged according to manufacturer instructions and transported
to the molecular biology lab on the same day. Some donations were
eventually kept refrigerated and transported at 4 - 8 oC to the molecular
biology lab on the following day. All donations were tested in parallel
at the serology lab for the mandatory screening tests (anti-HCV, anti-
HTLV-I/II, anti-HBc and HBsAg, anti-HIV 1 and 2, Chagas, Syphilis,
and abnormal hemoglobin detection). Donations were collected
between July 1st 2001 and February 28th 2006 at blood banks in São
Paulo city (Hospital Sírio Libanês, Hospital Nove de Julho, Hospital
Oswaldo Cruz, Hospital Evaldo Foz), Bragança Paulista (Núcleo de
Hemoterapia de Bragança Paulista, São Paulo State) and Brasília
(Hemolago, Federal District). More than 95% of the donors lived in
São Paulo city at the time of donation.
b) Serology
b1) Anti-HIV: In compliance to the Brazilian legislation12, two tests
with distinct antigenic composition were adopted. In the time period
described, a combination of either two assays from ABBOTT (AXSYM
MEIA HIV ½ gO, or Anti_HIV ½ 3rd Generation PLUS, Wiesbaden -
Delkenheim, Germany), MUREX Ice HIV 1.0.2 (Singapore Science
Park, Singapore) or ORTHO Anti-HIV 1+2 Ab Capture (Amersham,
Bucks, UK) were performed, according to manufacturer’s instructions.
b2) Western blot: For EIA repeatedly reactive donations, HIV Blot 2.2
(Genelabs Diagnostics, Syngapore) was performed on a new sample,
collected upon return of the donor to the blood bank. Reactivity was
assigned according to manufacturer’s guidelines.
c) NAT method: The process of donations pooling, RNA extraction
and cDNA synthesis are described in an accompanying article20.
c1) Multiplex PCR: 10 µL of cDNA was added to a PCR mixture
containing six primers (HCV, HIV, Control, Table 1), glycerol 5%,
cresol red 0.25 µg/µL, dNTPs 0.2 mM (A,C,G,U), 1.25 U of Platinum
Taq (Invitrogen, São Paulo, Brazil), 0.03U of Uracyl-N-Glycosilase
(Amersham, São Paulo, Brazil) in a final volume of 25 µL. This mixture
was submitted to the following thermocycling parameters: 95 oC for
five minutes, then 40 cycles of 94 oC /30 seconds; 55 oC/30 seconds;
65 oC/ one minute, and a final incubation step at 65 oC for seven minutes.
HIV LTR primers were described by CLELAND et al.3.
c2) Electrophoresis: PCR products from the External Control (EC,
308 bp), the HCV Untranslated Region (268 bp) and HIV Long-
Terminal Repeat (LTR, 188 bp) were run at 200mV/100mA for one
hour on an ethidium bromide stained 3% agarose gel and directly
observed under UV light on an UV Imager (Ultra-Violet Products,
Cambridge, UK). All images were digitalized and stored, allowing the
traceability of the results. A legend was engraved on the gel image and
a photo printed in a thermal printer, accompanying the daily working
sheet.
c3) Validation of NAT: This method was validated for routine use by:
c3.1) Sensitivity: Lyophilized WHO standards, purchased from the
National Institute for Biological Standards and Controls (NIBSC, Potters
Bar, Herts, UK, HIV-RNA International Standard Cat. # 97/656 I) were
reconstituted in RNAse free-ddH2O and diluted with negative plasma to
the desired concentrations. Twenty replicates were run three times at
five dilution points namely 1,000 IU/mL; 500 IU/mL; 250 IU/mL; 50
IU/mL and 10 IU/mL of HCV-RNA. The detection threshold of the
method was 500 IU/mL HIV-RNA (95% hit rate, Table 2).
c3.2) Specificity: On testing 1,000 seronegative donations there was
no sample assigned as “initially reactive”. In quality control blind
panels, no negative sample was assigned as reactive.
c3.3) Reproducibility: Assessed by running in parallel to serological
routine for two months and performance of three distinct operators.
The method was shown to be robust and reproducible, independent of
operator, provided that the technician was properly trained.
c3.4) Genotypic coverage: HIV-RNA Genotype Panel for NAT (NISBC
code 01/466) was purchased from NISBC. Panel contains samples
representing subtypes A, B, C, D, AE, F, G, AG-GH, group N and
group O. All samples were detected by the method both individually
(Fig. 1) and in pools.
Table 1
Primers used in the NAT Multiplex assay
Primer Sequence 5’→3’
HCV 5’ UTR Primers
SM 3 (sense) CTAGCCATGGCGTTAGTA
HC 18 (antisense) GGTGCACGGTCTACGAGACCT
PAW 109 RNA Primers (External Control)
DM 151 (sense) GTCTCTGAATCAGAAATCCTTCTATC
DM 152 (antisense) CATGTCAAATTTCACTGCTTCATCC
HIV LTR Primers
LTR A1352 (sense) GRAACCCACTGCTTAASSCTCAA
LTR A1353 (antisense) TGTTCGGGCGCCACTGCTAGAGA
Table 2
Sensitivity estimation of the test when challenged against a quantified
international standard
HIV-RNA International Reactive samples/
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c3.5) External assessment: Yearly participation on blind panels
prepared for quality control on NAT labs (Viral Quality Control Program
VQC, organized by CLB, Amsterdam, Netherlands). All samples
containing more than 500 IU/mL of HIV-RNA were correctly assigned
as reactive. No false-positives were observed.
d) Seroconversion samples: Two HIV seroconversion samples were
tested. They were included as they were regular donations and readily
detected by our method. One is a p24 Ag reactive sample detected at
our laboratory19 and the other is a NAT-only reactive donation detected
at another service18 and generously provided to us by Dr. Orlando Costa
Ferreira Jr. (Blood Bank, Hospital Israelita Albert Einstein, São Paulo,
Brazil). We also determined the viral load from both samples; the former
contained more than 750,000 copies/mL while the latter harbored
22,150 copies/mL.
e) Confirmatory NAT assays: Repeatedly reactive samples were
submitted to an alternative NAT test, either on the same sample or
from a new one collected from the donor. HIV repeatedly reactive
samples were submitted to a commercial HIV viral load method (Roche
HIV-Monitor v 1.5) by an ultra-sensitive procedure with a threshold of
50 copies/mL according to the manufacturer instructions.
f) Controls: On each run four controls were included from the
extraction; triplicates of the reconstituted international standards
containing 500 IU/mL of both HCV and HIV-RNAs and one
seronegative and NAT negative plasma. An amplification control was
included at the PCR step consisting of a “pool” of cDNAs from these
standards, previously shown to correctly amplify HCV and HIV. It
was required two out of three replicates to amplify HCV and HIV
RNA to validate the entire run. A negative result for HCV and HIV
RNA on the negative control was mandatory; otherwise every reactive
result was considered invalid. A positive result for the external control
on the “no DNA” tube made the full run invalid. The previously obtained
cDNA “pool” from standards served to guide us in case of a run failure,
i.e. if the run was completely negative, but this amplification control
was correct, we would have started again from extraction; if this control
failed we started from the PCR step onwards. Fig. 2 is an example of
such a routine run.
RESULTS
a) Blood Donors Screening: The method described above has been in
use as a routine since July 2001, replacing p24 Ag detection. Until
February 2006, a total of 102,469 donations were tested for HIV RNA.
35,906 PCR reactions were performed, counting pools and controls.
Forty-one samples were NAT initially reactive (0.04%) demanding their
testing individually on the next day routine. 1,147 samples were blocked
for inadequacy (1.12%; external control non-reactive) demanding their
inclusion in pools in the next day routine. By serology, 366/102,469
donations (0.36%) were rejected due to repeatedly reactive results,
while NAT rejected 41/102,469 (0.04% - see Table 3). There was one
NAT false positive (1/102,469 or 0.001%), which was negative for the
NAT HIV confirmatory assay and one confirmed NAT-only donation
(1:102,469). All blot reactive samples were concomitantly PCR reactive
and the negative concordance was 100% as well (Table 4). All blot
indeterminate samples were NAT non-reactive.
b) Seroconversion sample: One donation was identified as NAT
reactive/EIA non-reactive. According to the working flow, this sample
HIV+ = positive control consisting of HIV WHO Standard at 500 IU/mL. PL = plasma sample non-reactive
for HCV and HIV antibodies and RNAs. C+ = a pool of cDNAs from HIV and HCV Standards. MW =
molecular weight marker, 100bp ladder (Invitrogen, São Paulo, Brazil). EC = External Control. No = no
DNA control, H2Odd was added to the PCR mix.
Fig. 1 - Validation of multiplex NAT for genotypic coverage with a panel containing HIV
subtypes A-H (group M), and groups N and O.
MW = molecular weight marker 100bp ladder (Invitrogen, São Paulo, Brazil). Controls+ = 3 positive controls
containing each 500 IU/mL of both HCV and HIV RNA, the fourth is a cDNA of these generated previously;
RPT Ser and RPT Pla = An HIV NAT reactive donation detected in the previous day and repeated individually
from both serum and plasma; PL = HCV and HIV RNA negative plasma; No = no DNA control, H2Odd
was added to the PCR mix.
Fig. 2 - Routine analysis in a rare situation where both HCV (pools 2 and 9) and HIV (pools
6 and 11) reactive donations were detected. Pools are numbered from left to right.
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was re-tested individually on the next day, displaying again a reactive
result. The confirmatory assay showed a viral load of 8,310 copies/
mL. This donor was invited to return and provided another blood
sample, which exhibited seroconversion (Table 5). The index sample
was concomitantly reactive for anti-HBc. Donor is a male, 29y,
heterosexual, who denied any behavior of risk for HIV acquisition in
the period preceding the first donation.
Sequencing of the protease and reverse transcriptase genes revealed
the presence of the M36I polymorphism in the protease sequence, which
is compatible to an antiretroviral naïve isolate. Phylogenetic analysis,
available through the Brazilian HIV Genotyping Algorithm site (http://
www.aids.gov.br/genotipagem) classified this isolate as a circulating
recombinant form B/F1, which is commonly found in HIV-infected
persons in São Paulo city14.
DISCUSSION
We have demonstrated the feasibility of the routine use of an NAT
“in-house” method for screening of blood donations for HCV and HIV-
RNA. The methodology presented a high sensitivity and specificity
and the yield of NAT-only HIV donations was 1:102,469.
In our country, there are only a few theoretical exercises on the
virtual NAT yield if applied to the Brazilian blood supply. KUPEK9
has shown that contrary to what has been postulated and observed in
practice in most countries, the residual risk in Santa Catarina State is
higher for HIV (between 1:10,000 - 1:20,000) than for HCV
transmission (around 1:100,000). BARRETO et al.2 obtained a
magnitude of risk of HIV transmission of 14.9 per million donations,
based on first-time blood donors in São Paulo city, similar to AMORIM
et al.1 for Rio de Janeiro donors. NAT data on Brazilian plasma, sent
abroad in exchange for blood derivatives, has shown two reactive cases
for HIV RNA among 1,159,241 putative EIA negative donations tested
(1:579,620)11. Although these plasmas came from all Brazilian regions,
it should be borne in mind that São Paulo and Rio represent a significant
fraction of the donated blood in Brazil. This data must be interpreted
with caution, since it is not informed the brand and type of antibody
assay by which these donations were screened, neither if the
corresponding donors were traced back and tested for seroconversion
and confirmatory NAT assays. However, it shall be pointed out that the
numbers from the exported plasma are closer to the international
experience and provides a NAT HIV yield thirteen times smaller than
the estimate of BARRETO et al.2 and AMORIM et al.1 (1:33,333), as
illustrated in Table 6. In the US, a recent compilation of the data16
shows a yield of NAT isolated HIV reactive donations of 1:3,100,000,
which is three times lower than previous estimates (1:1,000,000)14.
This discrepancy may be interpreted as if these calculations had
overestimated the yield of NAT in Brazil. This could be due to the great
deviations of these estimations with large confidence intervals. If we
assume, for the numbers collected in this study, either a Poisson or a
Table 3
HIV-NAT/EIA results (n = 102,469 donations)
Test result n %
Rejected for (EIA) anti-HIV* 366 0.36
Rejected for HIV-NAT 41 0.04
EIA non-reactive/ NAT reactive 2@ 0.002
* Donations repeatedly reactive for one or two EIA anti-HIV tests. @ One sample
was not reactive by the NAT confirmatory method (false-positive), the other truly
NAT-isolated donation is described in detail in the text.
Table 4
HIV-RNA/Western blot results (n = 366 EIA repeatedly reactive donations + 1
NAT-only)
W. Blot NAT n (%)*
Reactive Reactive 33 13
Reactive Non-reactive 0 0
Non-reactive Reactive 0 0
Non-reactive Non-reactive 162 62
Indeterminate Reactive 1# 0.4
Indeterminate Non-reactive 64 24.6
Not done Reactive 6 -
Not done Non-reactive 101 -
 Total 367 100
* Excluding the 107 samples for which Western blot was not done because a second
sample was not provided. # The single NAT-only sample that according to the
standard procedure wouldn’t be submitted to W. blot since it was EIA non-reactive.
Table 5
Laboratory data from a NAT+/EIA- donor, detected in the window period
Date Anti HIV A Anti HIV B NAT Viral load Western blot
(Abs/Cut-off) (Abs/Cut-off) copies/mL
27/2/6 NRT NRT RT 8,310 Ind p24+ weak
Index donation (log10 = 3.92) Conclusion: Indeterminate
9/3/6 2.0/0.198 (RT) 1.91/1.00 (RT) RT > 750,000 Ind p24+ weak
Conclusion: Indeterminate
20/3/6 2.0/0.181 (RT) 6.25/1.00 (RT) RT > 750,000 gp160 weak/gp 120 weak/p24 weak
Conclusion: Reactive
NRT = Non Reactive; RT = Reactive
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binomial distribution and a confidence interval of 95%, we get a very
wide range for the NAT yield (1:4,048,583 - 1:18,382), emphasizing the
limited epidemiological value of the data presented in this paper,
principally because of the still relatively small sampling size.
Also, one can hypothesize that the larger risk predicted by
BARRETO et al.2 and AMORIM et al.1 was reduced by the pooled
analysis with plasma coming from Brazilian regions presenting much
lower risk. In addition, Brazilian plasma was tested in pools of 96 -
1,000 samples11. This large dilution factor could have contributed to
the low yield observed. Knowing the origin of the NAT isolated reactive
donations would certainly increase the scientific basis of the debate,
but unfortunately this information is yet not published.
Possibly, a degree of uncertainty on the data stems from an
unpredictable donor behavior; those willing to donate in order to be
HIV tested, especially shortly after incurring on risky practices8. This
may explain why we found an HIV p24 Ag reactive sample19 before an
isolated HCV-NAT one, and another hospital in São Paulo found the
same18. If this kind of behavior is more often found in large cities like
São Paulo, it would justify our findings and the contrast to what was
observed on the exported plasma. However, the striking approximation
of the rate of the two seroconversions detected by us; 1:103,740
(p24 Ag19) and 1:102,469 (NAT, this article) suggests that in our donor
population, the NAT-only HIV yield shall be around 1:100,000
donations.
Certainly, there are advantages and disadvantages of developing
and routinely performing an “in-house” method. Lower cost,
technological independence and agility to adapt for the detection of
emergent agents may be arguments in favor of homebrew assays. On
the other hand, it is unarguable that high-quality commercial kits
provide lot-to-lot consistency, guaranteed performance and reagent
stability that can hardly be accomplished by university and blood bank
laboratories, unless a rigid control of the process is followed.
In conclusion, the decision of implementing NAT testing for HIV
is, nowadays, not limited by the technical performance of the assays,
either for “in-house” or commercial tests available. What makes its
introduction not widely available is the high cost associated. Certainly
in the future, when such methods become more accessible, NAT will
be a routine test in hemotherapy, and probably “pooling” won’t be
necessary anymore. At this moment we believe that NAT-HIV is still
not a mandatory test for blood and hemocomponents used for
transfusional purposes by the Brazilian national blood system because
of its unfavorable cost-benefit analysis. However, if hemoderivatives
are to be manufactured from unused fresh frozen plasma, NAT will be
mandatory in order to cope with international GMP standards for the
plasma industry.
Due to scientific, economic and operational reasons we believe
that NAT for Blood Banks, if and when introduced, shall be executed
on a few specialized and trained molecular biology laboratories, which
would analyze hundreds to thousands donations daily.
RESUMO
Substituição do teste de p24 Ag (HIV) por um RT-PCR multiplex
na triagem primária de doadores de sangue
O uso de testes de ácidos nucleicos (NAT) na rotina de triagem de
doadores de sangue tornou-se uma realidade ao final da década de 1990.
Descreve-se aqui uma metodologia de RT-PCR multiplex “in-house”
que permite a detecção simultânea dos RNAs dos vírus HIV e HCV
além de uma molécula artificial de RNA usada como controle externo.
O método detecta todos os subtipos de HIV do grupo M e também do
grupo N e O, com uma sensibilidade de 500 UI/mL. Após validação,
este teste substituiu o do antígeno p24, até então na rotina de triagem
em nosso laboratório, desde 1996. De julho de 2001 a fevereiro de 2006
foram testadas 102.469 doações e 41 (0.04%) foram NAT reativas. Uma
doação NAT isoladamente reativa (anticorpo não-reativa) foi detectada
com soroconversão subseqüente do doador, portanto, o rendimento do
NAT nesta população até o presente momento é de 1:102.469. Este
número contrasta com a experiência obtida internacionalmente, onde
taxas de 1:600.000 - 1:3.100.000 foram descritas.
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Table 6
Residual risk of HIV transmission from serologically negative donations at different Brazilian blood banks
Center Risk Time Period Reference
Estimates
HEMOSC 1:10,000 - 1:20,000 1999 - 2001 KUPEK, E. (2004)
HEMORIO 1:33,333 1997 - 2000 AMORIM, L. et al. (2002)
HEMOSP(First-time donors) 1:50,000 - 1:100,000 1998 - 2001 BARRETO, C. et al. (2005)
HEMOSP(Repeat donors) 1:64,000 1996 - 1998 SABINO, E. et al. (1999)
Observed yields
Exported Brazilian plasma 1:580,000 2002 - 2003 MAC DOWELL, B. et al. (2004)
Several private blood banks 1:103,000 1996 - 2001 WENDEL, S. et al. (2002)
Several private blood banks 1:103,000 2001 - 2006 LEVI, J.E. et al. (this paper)
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